<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00975663</url>
  </required_header>
  <id_info>
    <org_study_id>I07038</org_study_id>
    <nct_id>NCT00975663</nct_id>
  </id_info>
  <brief_title>Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation</brief_title>
  <acronym>BASALT</acronym>
  <official_title>Evaluation of the Interest of Therapeutic Drug Monitoring of Immunosuppressants (Tacrolimus, Mycophenolate Mofetil) Based on Bayesian Estimation During the Three First Years Following Lung Transplantation, in Patients With or Without Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate in lung or heart-lung transplant patients on
      tacrolimus and mycophenolate the impact of optimized mofetil (MMF) therapeutic drug
      monitoring and dose adjustment of both drugs on the incidence of treatment failure over the
      first three years post-transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research will be based on a prospective randomized trial comparing optimized TDM of
      tacrolimus and MMF to the current strategy of tacrolimus and MMF dose adjustment in lung
      transplant recipients. The study will focus on the first three years post-transplantation, as
      treatment failures (including BOS) occur mainly during this post-transplantation period. As
      the aim of tacrolimus and MMF dose individualization is to avoid over- or underexposure, for
      the purpose of this study treatment failure will be a composite criterion gathering events
      which reflect both over- and underexposure to tacrolimus and MMF.

      Optimized TDM of tacrolimus and MMF based on blood tacrolimus and plasma MPA AUC Bayesian
      estimation will be compared to current strategies: tacrolimus dose adjustment based on trough
      levels (C0) and administration of a standard dose of MMF, decreased by the pulmonologist in
      case of adverse drug reactions or increased in case of inefficacy. The efficacy of optimized
      strategy vs. current strategies will be mainly evaluated through the incidence of treatment
      failure.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunosuppressive treatment failure</measure>
    <time_frame>Day 7, day 14, day 21; months 3, 6 and every six months afterwards up to 3 years posttransplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy score</measure>
    <time_frame>Day 7, day 14, day 21; months 3, 6 and every six months afterwards up to 3 years posttransplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity score</measure>
    <time_frame>Day 7, day 14, day 21; months 3, 6 and every six months afterwards up to 3 years posttransplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit/risk ratio</measure>
    <time_frame>Day 7, day 14, day 21; months 3, 6 and every six months afterwards up to 3 years posttransplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Each event composing the composite criterion</measure>
    <time_frame>Day 7, day 14, day 21; months 3, 6 and every six months afterwards up to 3 years posttransplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall cost of patients monitoring</measure>
    <time_frame>Day 7, day 14, day 21; months 3, 6 and every six months afterwards up to 3 years posttransplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetic and proteomic analysis</measure>
    <time_frame>Day 7, day 14, day 21; months 3, 6 and every six months afterwards up to 3 years posttransplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Lung and Heart-lung Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Optimized TDM of tacrolimus and MMF dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current tacrolimus and MMF dosing strategies</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus and MMF</intervention_name>
    <description>Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus and MMF</intervention_name>
    <description>Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male and female patients aged 18 years or more

          -  CF and non-CF patients receiving single-lung or double-lung or heart-lung
             transplantation for the first time

          -  Patients on oral tacrolimus and MMF for at least 48 hours at the time of inclusion
             (administration via a naso-gastric tube possible if necessary)

          -  Patients without progressive chronic pathology jeopardizing short term patient and
             graft survival

          -  Patients accepting to comply with at least the evaluation visits planned in the
             investigation center over the first three years post-transplantation (D7, D14, M1, M3,
             M6, M12, M18, M24, M30, M36)

          -  Patients giving their free and informed written consent to participate in this study

          -  Patients with a health insurance policy or registered under a health insurance program

        Exclusion Criteria:

          -  Patients aged less than 18 years or patients over 18 years under guardianship

          -  Patients who disagree with this research

          -  Patients with a contra-indication to receiving tacrolimus or MMF

          -  Patients on cyclosporine, sirolimus or everolimus

          -  Patients who have already benefited from a solid organ transplantation in the past
             (including lung or heart-lung transplantation)

          -  Patients infected by Burkholderia cenocepacia (Burkholderia cepacia genomovar III)

          -  Patients receiving HIV protease inhibitors (major pharmacokinetic interaction with
             tacrolimus)

          -  Pregnant or breastfeeding women or those of child-bearing age who do not use an
             efficient contraceptive method

          -  Drug users or patients suffering from neuro-psychiatric disorders preventing them from
             both proper comprehension of the protocol and reliable consent

          -  Patients already participating in another interventional clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre MARQUET, MD</last_name>
    <role>Study Director</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Pneumologie</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pôle Médecine Aiguë et Communautaire, Clinique de Pneumologie,</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, HCL Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ApHm -Chirurgie thoracique</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie-CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Cardiovasculaire - Hôpital Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - CH de Suresnes</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - Phtisiologie - Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2009</study_first_submitted>
  <study_first_submitted_qc>September 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2009</study_first_posted>
  <last_update_submitted>April 23, 2011</last_update_submitted>
  <last_update_submitted_qc>April 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Marie SENGELEN</name_title>
    <organization>CHU Limoges</organization>
  </responsible_party>
  <keyword>Lung transplantation</keyword>
  <keyword>heart-lung transplantation</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>mycophenolate</keyword>
  <keyword>immunosuppressant</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

